secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jade Biosciences, Inc. (JBIO)
CIK:        0001798749
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0001193125-25-119856
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.01, 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jade Biosciences Q1 2025 net loss $38.2M, cash $49.9M, merger closed Apr 28
---------------------------------------------------------------------------

- Net loss of $38.2M for Q1 2025; R&D expenses $20.0M, G&A $3.4M; change in fair value of convertible notes added $15.4M to other expense.
- Cash and equivalents $49.9M as of March 31, 2025, down from $69.4M at Dec 31, 2024; expects existing cash plus $334.2M from Pre-Closing Financing to fund operations for at least 12 months.
- Merger with Aerovate Therapeutics completed on April 28, 2025; combined entity renamed Jade Biosciences, Inc., trades on Nasdaq as JBIO.
- Lead candidate JADE-101 (APRIL-targeting antibody) for IgA nephropathy; two preclinical programs JADE-002 and JADE-003 in antibody discovery.
- Company had $123M in convertible notes payable (including $26M related party) and $2M warrant liability as of March 31, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1798749/000119312525119856/0001193125-25-119856-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1798749/000119312525119856/d72148d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-119856

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer